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muscle regeneration through synergistic
action of extracellular vesicle cargo and
soluble proteins
Robert Mitchell1, Ben Mellows1, Jonathan Sheard2,3, Manuela Antonioli4, Oliver Kretz5,6, David Chambers8,
Marie-Theres Zeuner2, James E. Tomkins2, Bernd Denecke9, Luca Musante10, Barbara Joch7,
Florence Debacq-Chainiaux11, Harry Holthofer10,12, Steve Ray13, Tobias B. Huber5,6,12,14, Joern Dengjel12,15,
Paolo De Coppi16, Darius Widera2* and Ketan Patel1,12*Abstract
Background: The mechanisms underpinning the regenerative capabilities of mesenchymal stem cells (MSC) were
originally thought to reside in their ability to recognise damaged tissue and to differentiate into specific cell types that
would replace defective cells. However, recent work has shown that molecules produced by MSCs (secretome),
particularly those packaged in extracellular vesicles (EVs), rather than the cells themselves are responsible for tissue repair.
Methods: Here we have produced a secretome from adipose-derived mesenchymal stem cells (ADSC) that is free of
exogenous molecules by incubation within a saline solution. Various in vitro models were used to evaluate the effects of
the secretome on cellular processes that promote tissue regeneration. A cardiotoxin-induced skeletal muscle injury model
was used to test the regenerative effects of the whole secretome or isolated extracellular vesicle fraction in vivo. This was
followed by bioinformatic analysis of the components of the protein and miRNA content of the secretome and finally
compared to a secretome generated from a secondary stem cell source.
Results: Here we have demonstrated that the secretome from adipose-derived mesenchymal stem cells shows robust
effects on cellular processes that promote tissue regeneration. Furthermore, we show that the whole ADSC secretome is
capable of enhancing the rate of skeletal muscle regeneration following acute damage.
We assessed the efficacy of the total secretome compared with the extracellular vesicle fraction on a number of assays
that inform on tissue regeneration and demonstrate that both fractions affect different aspects of the process in vitro and
in vivo.
Our in vitro, in vivo, and bioinformatic results show that factors that promote regeneration are distributed both within
extracellular vesicles and the soluble fraction of the secretome.
Conclusions: Taken together, our study implies that extracellular vesicles and soluble molecules within ADSC secretome
act in a synergistic manner to promote muscle generation.
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Mesenchymal stem cells (MSCs) are an attractive thera-
peutic tool for regenerative medicine due to their cap-
acity for self-renewal and the ability to differentiate into
a variety of mesodermal lineages [1, 2]. It has been pos-
tulated that due to their inherent multipotency, MSCs
are able to directly integrate into diseased organs and
tissues [3]. In this context, transplantation of MSCs has
been reported to be beneficial in cartilage regeneration
[4], regeneration of bone tissue [5] and in acute and
chronic models of muscle degeneration [6, 7]. However,
although these and other studies reported an abrogation
of pathology, the level of MSC engraftment into the dis-
eased organs is often negligible (less than 1%) [8–10].
This led to an alternative hypothesis suggesting that fac-
tors produced by MSCs acting in a paracrine manner ra-
ther than the cells themselves promote tissue regeneration
[11–15]. To date, the regenerative effect of factors se-
creted by MSCs have been investigated in many different
conditions including regeneration of the heart [16], central
nervous system (CNS) [17], kidney [18], muscle tissue [19]
and wounds [20] suggesting that the MSC secretome may
be as efficacious as the cells themselves. Many studies
have also described MSCs as having immune-privilege po-
tential, with several MSC products being approved for
clinical application [21, 22].
Stem cells are known to interact and actively commu-
nicate with their surrounding microenvironment [23] via
the secretion of cytokines and growth factors including
but not limited to insulin-like growth factor-1 (IGF-1)
[24], hepatocyte growth factor (HGF) [3], interleukins
[25] and vascular endothelial growth factor (VEGF) [26].
These molecules regulate a variety of different cell activ-
ities essential in tissue regeneration, such as prolifera-
tion, angiogenesis and the modulation of inflammation
[21, 27, 28]. Proteins secreted by stem cells are found ei-
ther as free entities or within membrane particles such
as exosomes and microvesicles (MV), collectively known
as extracellular vesicles (EVs). Originally considered to
be cellular debris, EVs are now understood to play a vital
role in cell-to-cell communication [29, 30] and may me-
diate the immunomodulatory effects of MSCs [31]. In
addition to proteins, mRNA, miRNA and organelles are
packaged within EVs [32–34] which collectively consti-
tute the stem cell secretome.
Human adipose tissue is easily accessible and a
source of multipotent MSCs that can be applied for au-
tologous transplantation [35]. In addition to mediating
bone and cartilage regeneration, ADSCs have been re-
ported to positively modulate endogenous regeneration
of muscle [36, 37].
Recently, we reported that the secretome from human
amniotic fluid stem cells (AFSCs) has anti-inflammatory
properties, promotes stem cell proliferation, protectsagainst cellular senescence and facilitates tissue regener-
ation in a cardiotoxin (CTX)-induced model of muscle
degeneration [38].
In the present study, we wanted to investigate if the
application of the same isolation method would produce
an ADSC secretome that has similar regenerative poten-
tial and if the EV fraction was solely responsible for
these effects. Furthermore, we have taken a bioinfor-
matic approach to compare the protein and molecular
components of the ADSC secretome with the secretome
of AFSCs that also promotes muscle regeneration.
We show that the secretome produced using our
protocol contained mostly EVs, rich in miRNA and not
mRNA. Assessing the biological activity of the whole
ADSC secretome, we demonstrate that similar to AFSC
secretome, it is capable of promoting cell proliferation
and migration.
Importantly, we show that the whole secretome and
the EV fraction have a differing impact on the ability to
protect against senescence and in a molecular model for
inflammation based on nuclear translocation of NF-κB.
In order to comparatively assess the biological activity
of both fractions in vivo, we used the CTX model of
acute muscle injury. Both fractions increased the
cross-sectional area of newly regenerated muscle fibres
and reduced the numbers of infiltrating macrophages
with the EV fraction resulting in significantly stronger
effects. However, we detected significant differences be-
tween the impact of the whole secretome and the EV
fraction on the muscle stem cells during regeneration.
Mass spectrometry was performed to determine the
ADSC-EV protein cargo and proteins present in the sol-
uble fraction alone. Bioinformatic analysis revealed 96
proteins exclusively present in the soluble and 301 in the
EV fraction of the secretome.
Analysis of the miRNA cargo of the EVs revealed a broad
range of miRNAs present in samples from three individual
donors targeting pathways regulating the stress response,
differentiation, proliferation and immune modulation.
Our comparison of ADSC and AFSC secretomes re-
vealed 108 mutually exclusive protein hits in the EV
fractions of both secretomes and 50 proteins present in
both soluble fractions. A comparison of the miRNA
cargo of EVs from ADSCs and AFSCs revealed 519 mu-
tually exclusive miRNAs and only 47 miRNA exclusively
present in ADSC EVs.
In conclusion, our results indicate that the EV-cargo is
mainly but not exclusively responsible for the regenera-
tive action of the ADSC secretome in CTX-induced
muscle injury model. Moreover, our data implicates that
the beneficial effects of the paracrine factors are a result
of a synergistic action of the miRNA and protein cargo
of the EV fraction and the soluble proteins within the
total secretome.
Mitchell et al. Stem Cell Research & Therapy          (2019) 10:116 Page 3 of 19Materials and methods
Cell culture
Human ADSCs (Life Technologies, Cat # 510070) were
cultured in MesenPro RS™ (Life Technologies, 12746-
012) supplemented with 1% L-glutamine (Life Technolo-
gies, 25030-081) and 1% penicillin streptomycin (Life
Technologies, 15070-063). All experiments were carried
out with cells at passage 6 or below.
Human lung fibroblasts (IMR-90) were used at 50%
Hayflick limit (27–32 population doublings) and cul-
tured in αMEM supplemented with 10% FBS (Life Tech-
nologies 10500-064), 1% L-glutamine and 1% penicillin
streptomycin.
Human U251-MG Glioblastoma cells (U251) (Cell
Line Service) were cultured in high glucose DMEM sup-
plemented with 10% FBS, 1% L-glutamine and 1% peni-
cillin streptomycin.
A10 rat smooth muscle cells were cultured in high
glucose DMEM supplemented with 10% FBS and 1%
L-glutamine.
C2C12 cells were cultured in DMEM supplemented
with 10% FBS, 1% L-glutamine and 1% penicillin strepto-
mycin and differentiated in DMEM supplemented with
2% horse serum, 1% L-glutamine and 1% penicillin
streptomycin.
NHDF Fibroblast cells (Lonza, Cat # CC-2511) were
cultured in DMEM supplemented with 10% FBS, 1%
L-glutamine and 1% penicillin streptomycin.
ADSC secretome generation and extracellular vesicle (EV)
isolation
ADSCs cultivated as adherent monolayer were harvested
via enzymatic dissociation (TrypLE™ Select, Life Tech-
nologies, 12563-011) and washed 3× in sterile 1× PBS
(Life Technologies, 10010-056) with centrifugation at
300g for 5 min at room temperature (RT) between
washes, before aliquoting 1 × 106 cells per tube. Each ali-
quot was pelleted and covered with 400 μL fresh sterile
PBS and maintained at room temperature for 24 h.
Thereafter, the supernatant was aspirated, pooled, sterile
filtered through a 0.2-μm syringe filter (Pall Life Sci-
ences, 4652) and centrifuged at 2000g for 20 min at RT
(and hereafter referred to as ‘total ADSC secretome’).
The whole secretome was ultracentrifuged at 200,000g
for 18 h at 4 °C. The supernatant was aspirated (soluble
fraction) and pellets re-suspended in PBS (40 μL/1 × 106
cells) to produce the EV fraction.
TEM and EV size analysis
A single drop of re-suspended EV pellet was placed onto
parafilm and adsorbed onto carbon-coated copper-
meshed grids by placing the latter onto the drops for 5
min. The samples were fixed with 1% glutaraldehyde,
washed four times for 30 s and negatively contrastedusing 1% uranyl acetate. Grids were air dried and ana-
lysed using a Zeiss 906 transmission microscope. EV size
was quantified by manually measuring the diameter of
EV populations from three separate batches of complete
secretome on Axiovision image analysis software (ver-
sion 4.7). Protein content of the whole secretome and
EV fraction was analysed by SDS PAGE followed by sil-
ver staining. Briefly, 6 μg of denatured protein was re-
solved on a 4–12% SDS PAGE gel prior to processing
with the SilverXpress® silver stain kit (Life Technologies
LC6100) and imaged using Syngene G:BOX using
GeneSys software.
EV concentration and size analysis using nanoparticle
tracking analysis
The concentration and the size of EVs within the whole
secretome was assessed using nanoparticle tracking ana-
lysis (NTA) as described in [39] using an NS500 instru-
ment (Nanosight Ltd., Amesbury, UK).
Assessment of EV uptake by IMR-90 cells
ADSC EV were labelled with fluorescent dye PKH67
(Sigma Aldrich MIDI67) by adding 40 μL of EV fraction
(EV from 1 × 106 cells) to PKH67 dye solution followed
by incubation for 5 min at room temperature before be-
ing ultracentrifuged at 200,000g for 18 h at 4 °C. Follow-
ing centrifugation, the supernatant was aspirated and EV
pellet resuspended in 100 μL PBS. For the cellular up-
take assays, IMR90 cells at 40% confluency were washed
3× with DMEM and incubated with 5 μM CellTracker™
Red (Invitrogen CMTPX) for 30 min at 37 °C, 5% CO2.
PKH67-stained EVs were added to CellTracker™
Red-stained IMR90 cells and incubated for 3 h at 37 °C,
5% CO2. The cells were fixed in 4% paraformaldehyde
for 15 min at room temperature, washed 3× in PBS and
sections mounted using mounting medium containing
2.5 μg/mL 4’,6-diamidino-2-phenylindole (DAPI) for nu-
clear visualisation. Confocal images were captured using
the Nikon A1-R inverted confocal microscope with the
Nikon Plan Apo VC 100x DIC N2 optic lens, running
NIS Elements AR.
Flow cytometry
ADSCs were fixed in 4% paraformaldehyde at RT for 20
min and non-specific binding blocked with 5% FBS.
Antibodies (multipotency markers: CD44 (Millipore,
CS208200 1:20), CD73 (BD Biosciences, 551123 1:20),
CD90 (BD Biosciences, 554895 1:10) and non-MSC
markers: CD34 (Millipore CBL555F 1:20) and CD45 (BD
Biosciences, 554875 1:10)) were incubated for 1 h at 4 °
C. Ten thousand events were profiled by flow cytometry
(BD Accuri C6 Flow Cytometer, C-sampler) followed by
data analysis in FlowJo, LLC v10.
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For assessment of adipogenic and osteogenic potential
after secretome collection, 4000 cells/cm2 were plated
and cultured to 95% confluency before growth media
were replaced with either adipogenic (R&D Systems
CCM007 and CCM011) or osteogenic (Life Technologies
A10069-01 and A10066-01) differentiation media for 21
days. Adipogenesis or osteogenesis was determined by
Oil Red O (Sigma Aldrich O0625) or Alizarin Red S
(Sigma Aldrich A5533) staining respectively. Bright field
images were captured immediately after staining. Chon-
drogenic potential was assessed by resuspending 1 × 106
ADSC cells in a 1.5-mL tube and allowing the formation
of a pellet by gravity. The pelleted cells were incubated
in differentiation media (Life Technologies A10069-01
and A10064-01) for 21 days with a media change every
3 days. Thereafter, the ADSC pellet was embedded in tis-
sue freezing medium and cryosectioned at 13 μm. Chon-
drogenic cells were identified with 0.1 mg/mL Alcian
Blue staining solution (Sigma Aldrich A5268) [40].
Proliferation assay
C2C12 cells were seeded into 6-well cell culture plates
(Sarstedt) at 3000 cells/cm2 and allowed to adhere for
24 h. Two percent whole secretome (v/v) in growth
media was added to the cells followed by incubation for
48 h and manual cell counting using a haemocytometer.
Differentiation assay
C2C12 cells were seeded into 6-well plates (Sarstedt) at
3000 cells/cm2 and cultured in growth media until they
reached 95% confluency, where the growth media was re-
placed with differentiation media supplemented with 2%
whole secretome (v/v). The cells were further cultured for
72 h, fixed using 2% PFA and processed for immunocyto-
chemical staining using an antibody against Myosin Heavy
Chain (Millipore, 05-716, clone A4.1025 1:1).
Wound closure (migration) assay
A10 rat smooth muscle cells were seeded into a 24-well
plate (Sarstedt) at 36,000 cells/cm2 and incubated over-
night in standard growth media. Following incubation,
scratches were made with a p20 pipette tip vertically
through the well. Media within each well was removed,
and the cells were washed with 1 mL pre-warmed PBS.
The PBS was replaced with complete media supple-
mented with 2% (v/v) vehicle control (PBS) or 2% (v/v)
whole secretome. Migration was assessed using the
Nikon TiE imaging system where images were gathered
every 30 min over a 16-h period. Analysis was performed
on images taken at 0 h compared to those gathered at 6
h (where a ~ 50% gap closure was observed). Gap area at
6 h was quantified and presented as a percentage closure
relative to that at 0 h.Senescence assay
Stress-induced senescence was induced in IMR-90 cells
using H2O2 as previously described [41]. Briefly, 50,000
IMR-90 cells were cultured in a 12-well plate until 70%
confluent, at which point 10% secretome or 2% EV
(from 1 × 106 cells) (v/v) was introduced in growth
medium. Cells were incubated for 24 h before being ex-
posed to 100 μM H2O2 in growth medium for 2 h.
Thereafter, cells were washed twice in PBS, maintained
in growth media for 48 h, passaged and plated in a
24-well plate at 800 cells/well before staining for
β-galactosidase activity using X-Gal. Analysis of senes-
cent cells was carried out by manually counting the pro-
portion of cells stained blue on an inverted
epifluorescence microscope (Zeiss A1).Ethical approval
The experiments were performed under a project licence
from the United Kingdom Home Office in agreement
with the Animals (Scientific Procedures) Act 1986. The
University of Reading Animal Care and Ethical Review
Committee approved all procedures.Animal maintenance
Healthy male wild-type C57BL/6 mice (2–3 month)
were maintained in accordance with the Animals
(Scientific Procedures) Act 1986 (UK) under a project
licence from the United Kingdom (UK) Home Office.
Mice were housed under standard environmental con-
ditions (20–22 °C, 12–12-h light–dark cycle) and were
provided with food (standard pelleted diet) and water
ad libitum.Acute skeletal muscle degeneration
Non-immunosuppressed mice were warmed for 10 min
in a hot box at 40 °C prior to the intra-venous (IV) injec-
tion of 100 μL sterile 0.1M PBS, 100 μL whole secre-
tome or 100 μL EV (from 1 × 106 cells) through the
lateral tail vein (5 mice per condition). Thirty minutes
later, mice were anaesthetised with 5% isofluorane and
intra-muscular (IM) injected with 30 μL of 50 μM cardi-
otoxin I (CTX) from Naja pallida (Latoxan, Valence
France) into the right tibialis anterior (TA) muscle.
Thirty microlitre sterile PBS was injected into the left
TA which served as the undamaged control muscle.
Mice were then maintained for 5 days before being
humanely sacrificed via schedule 1 killing. Following cul-
ling, the TA muscle was snap frozen on frozen iso-
pentane before storage at − 80 °C. Thirteen-micrometre
cryosections were made using a Bright OTG cryostat
(OTF/AS-001/HS) for immunohistochemistry or histo-
logical examination.
Mitchell et al. Stem Cell Research & Therapy          (2019) 10:116 Page 5 of 19Histology, immunohistochemistry and cellular EV uptake
Acid phosphatase staining was analysed for compromised
muscle fibre integrity by incubating TA cryosections in
acid phosphatase buffer (HPR reagent, 0.1M acetate buf-
fer pH 5.0, 50mg/mL naphthol AS-BI phosphate) for 90
min at 37 °C before being washed and counterstained with
a 1:30 dilution of Harris haematoxylin for 1min. The
stained slides were mounted using hydromount.
Immunocytochemistry was performed as previously
described [42] with the following antibodies: monoclonal
anti-mouse Pax7 (DSHB-Pax7) (1:1), monoclonal
anti-mouse Myosin heavy chain 3 (DSHB-F1.652) (1:1),
Rat anti-mouse CD31 (BioRad MCA2388) (1:150), Rat
anti-mouse F4-80 (BioRad MCA497R) (1:200), poly-
clonal rabbit anti-MyoD (Santa Cruz sc-760) (1:200),
monoclonal mouse anti-CD68 (Abcam ab955) (1:200),
and monoclonal mouse anti-NF-κB-P65 (F-6) (Santa
Cruz sc8008) (1:200). Secondary antibodies used were
Alexa Fluor 488 Goat anti-mouse IgG (Invitrogen
A11029) (1:200), Alexa Fluor 594 Goat anti-Rabbit IgG
(Invitrogen A11012) (1:200), and Rabbit anti-Rat HRP
(DAKO P0450) (1:200). Sections were mounted using
mounting medium, containing 2.5 μg/mL 4’,6-diamidi-
no-2-phenylindole (DAPI) (Molecular Probes D1306) for
nuclear visualisation.
Sample preparation for mass spectrometry (MS) and
analysis
ADSC-EV (EV) and non-EV (soluble) fractions isolated
from ADSC secretome were obtained as described
above. Proteins were suspended in 1× SDS-PAGE load-
ing buffer, denaturated and reduced with 1 mM DTT for
10min at 95 °C, then alkylated using 5.5 mM iodaceta-
mide for 30 min at 25 °C in the dark. Proteins were re-
solved by SDS-PAGE using 4–12% Bis-Tris mini
gradient gels. Each lane was cut into 10 equal slices and
proteins therein were in-gel digested with trypsin. Pep-
tides were dried to less than 5 μl and resuspended in
15 μl of 0.5% acetic acid for the MS analysis.
LTQ Orbitrap XL mass spectrometer coupled to an
Agilent 1200 nanoflow-HPLC was used to measure pep-
tides derived from trypsin digestion. Samples, applied
directly onto self-packed HPLC-column tips of around
20 cm, were subjected to a gradient formed by solution
A (0.5% acetic acid LC–MS grade in water) and by in-
creasing organic proportion of solution B (0.5% acetic
acid in 80% ACN LC–MS grade in water) within 120
min [43]. MaxQuant software [44] version 1.4.1.2 was
used to identify proteins based on peptides profiles and
to perform label-free quantification. Both Orbitrap and
MaxQuant parameters were set as previously described
[45]. iBAQ quantification values were log2-transformed,
and subsequently, missing values were imputed by nor-
mal distribution. GO terms’ analyses for the entiredataset and for 269 proteins identified in all samples
were performed by principal component analysis consid-
ering the enrichment of 4 categories and using a cut-off
of Benjamini-Hochberg FDR lower than 0.05.Analysis of the miRNAs
GeneChip® miRNA 4.0 Arrays were used to analyse the
miRNA content of ADSC secretome (FlashTag™ Biotin
HSR RNA Labeling Kit according to the manufacturer’s
instructions was used). Probe cell intensity data (CEL)
from Affymetrix GeneChip® miRNA 4.0 Arrays were
analysed in the Affymetrix Expression Console™ soft-
ware. Normalisation was performed using the Robust
Multichip Analysis (RMA) + DABG algorithm [46]. Only
miRNAs calculated as present in all 3 samples were de-
clared as generally expressed after 24 h. Focus was given
to the miRNAs present with the highest signal intensities
(top 50). For these top 50 miRNAs, validated target
mRNAs were amalgamated using miRWalk2.0 software
[47]. In the next step, GO Slim classification for bio-
logical process was performed using WebGestalt soft-
ware to provide a high-level functional classification for
validated target mRNAs [48]. AltAnalyze software
(Version 2.1.0) was used to design the heat map showing
intensity variability between biological replica (n = 3) for
the top 50 (hierarchical clustering heat map using cosine
column and row clustering, rows were normalised rela-
tive to median).Protein functional annotation
Proteins identified in specific fractions of the ADSC
secretome were subjected to functional enrichment ana-
lysis to provide insight into the functional associations
of these protein subsets. This analysis was performed in-
dependently using g:Profiler g:GOSt [49] for enrichment
of biological process (BP) Gene Ontology (GO) terms.
Statistical significance was calculated using the Fisher
one-tailed test in combination with the default g:SCS al-
gorithm to correct for multiple testing. Inferred elec-
tronic GO annotations were not included, and data was
not subjected to hierarchical filtering. Significantly
enriched GO terms were grouped using an in-house se-
mantic ontology to aid interpretation [50].Statistical analysis
Statistical analysis was performed with GraphPad Prism
software using unpaired Student’s t test or a one-way
analysis of variance followed by post hoc Tukey’s test
unless otherwise stated. A minimum of 95% confidence
interval was used for significance; p values indicated on
figures were p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***).
Data was presented as mean ± SEM.
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ADSC secretome contains soluble proteins and EVs with
miRNA and proteins as a cargo
In order to visualise and quantify the protein compo-
nents within the total ADSC secretome, isolated EVs
(EV fraction) and EV-depleted secretome (soluble
fraction), SDS-PAGE with subsequent silver staining
was performed (Fig. 1a). Within the total secretome,
we were able to detect a wide spectrum of proteins
(10–260 kDa) with a concentration of 206.0 μg/mL
corresponding to 82.4 μg/million cells (Fig. 1a, b).
Analysis of the EV fraction revealed a concentration
of 125.1 μg/ mL (50.0 μg/million cells) whereas
803.9 μg/ mL (32.4 μg/million cells) of total protein
was detected in the soluble fraction (Fig. 1b). Notably,
each of the analysed fractions showed a distinctive
size distribution profile (Fig. 1a, b). Profiling the nu-
cleic acids content in the total ADSC secretome using
bioanalyzer PicoRNA chips identified the presence of
small RNAs with no molecules larger than 30 nucleo-
tides, suggesting that the RNA components are exclu-
sively miRNAs (Fig. 1c).
Characterisation of ADSC secretome EV
For visualisation, EVs were isolated from total ADSC
secretome using ultracentrifugation and processed for
TEM. Size distribution analysis revealed an average EV
diameter of 52.2 nm without the presence of larger parti-
cles (Fig. 1d, e). In order to verify the size distribution
and to determine the number of particles, nanoparticle
tracking analysis (NTA) was applied revealing 17.4 × 108
EVs/mL in a secretome derived from 2.5 × 106 cells
(Fig. 1f ). In accordance with the TEM analysis, NTA re-
sults indicated an average EV size of 57 nm (Fig. 1g).
ADSC-derived EV are taken up by IMR-90 cells
To monitor their uptake, ADSC-derived EVs were labelled
with PKH67 and incubated with IMR-90 cells. Subsequent
laser scanning microscopy and image analysis revealed
that ADSC-derived EVs were able to interact and to be
taken up by host cells as indicated by intracellular PKH67
signal in host cells (Fig. 1h, white arrow).
ADSCs do not change their characteristics following
secretome generation
In order to assess potentially detrimental effects that
the generation of the whole secretome may have upon
the ADSCs, we tested the viability, multipotency
marker expression and differentiation capability of
ADSCs 24 h after the secretome generation. We found
a viability of 71.2% (data not shown) and detected no
significant changes in the expression pattern of positive
and negative MSC markers. Ninety-five percent of the
surviving ADSCs after the PBS incubation periodremained positive for the mesenchymal stem cell
(MSC) markers CD44, CD73 and CD90 and displayed
less than 1% expression for the negative MSC markers
CD34 and CD45 (Additional file 1: Figure S1A-B). Fur-
thermore, the surviving cells readily differentiated into
osteogenic (Additional file 1: Figure S1C), adipogenic
(Additional file 1: Figure S1D) and chondrogenic cells
(Additional file 1: Figure S1E).
ADSC secretome promotes cell proliferation, skeletal
muscle differentiation and migration
Tissue regeneration and homeostasis rely on cell prolifera-
tion, stem cell differentiation and cellular migration. Thus,
we investigated the impact of the total ADSC secretome
on these three hallmarks of regeneration. Total number
determination of the mouse myoblast cell line C2C12 ex-
posed for 48 h to the total secretome revealed a significant
increase of cell proliferation compared to control cells
(Fig. 2a). Moreover, the total secretome was able to stimu-
late the differentiation of C2C12 cells towards myotubes
(Fig. 2b, c). To assess the effect of the total secretome on
cell migration, a wound closure assay was performed, re-
vealing no effect on migration in the presence of the
secretome compared to the control (Fig. 2d, e).
Total ADSC secretome and the EV fraction both protect
against cellular senescence, but only the EV fraction
reduces the levels of inflammation in U251 cells
Protection against cellular senescence was assayed by ex-
posure of IMR-90 cells to 100 μM H2O2. Forty-eight per-
cent of stressed cells treated with PBS showed ß-Gal
activity. In contrast, exposure of IMR-90 cells to the total
ADSC secretome prior to induction of stress stimulus re-
duced the ß-Gal activity to the level of unstressed control
cells (Fig. 2f). Notably, co-treatment with 100 μM H2O2
and the EV fraction resulted in a similar, yet non-significant
reduction of the proportion of ß-Gal-positive cells (Fig. 2f).
In order to comparatively assess the anti-inflammatory
potential of ADSC secretome and enriched ADSCs EV, we
investigated the effect of both fractions on the
TNF-α-induced nuclear translocation of the NF-κB sub-
unit p65 in U251 cells (Fig. 2g, h). Notably, the level of nu-
clear NF-κB p65 was significantly increased by TNF-α
treatment compared to control cells (Fig. 2g, h). Exposure
of TNF-α stimulated cells to the total secretome fraction
led to a slight and non-significant reduction of nuclear
p65 whereas the EV fraction resulted in a significantly re-
duced amount of p65 in the nuclei (Fig. 2g, h).
Regenerative effect of ADSC secretome is not replicated
in control fibroblast secretome
To investigate if the regenerative effects observed are in-
dicative to ADSC or can be observed via treatment with
any whole secretome, we generated a whole secretome
Fig. 1 ADSC secretome contains soluble proteins and EVs with miRNA and proteins as a cargo. a, b SDS-PAGE with subsequent silver staining of
the total ADSC secretome, EV fraction, and soluble fraction revealed a wide spectrum of proteins, with each fraction showing a distinctive size
distribution profile. c Profiling the nucleic acids content using bioanalyzer PicoRNA chips showed no molecules larger than ~ 31 nucleotides. d–g
The EVs were analysed using TEM and NTA revealing a size of ~ 50 nm. Scale bar: 100 nm. h EVs were labelled with PKH67 and incubated with
IMR-90 cells. Overlap between the PKH67 signal and phalloidin-stained cytoskeleton demonstrates that ADSC-derived EVs are taken up by IMR-90
cells (white arrow). Scale bar: 20 μm
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Fig. 2 Total ADSC secretome and the EV fraction affect three hallmarks of regeneration in vitro. a The impact of ADSC secretome on cell
proliferation was assessed using total cell number determination revealing a significant increase in proliferation after exposure of C2C12 cells to
the whole secretome. b, c Immunocytochemical analysis demonstrated an increase of C2C12 cell differentiation towards myotubes after whole
secretome treatment. d, e Wound healing assay was performed to assess the impact of the secretome on migration of A10 muscle cells. No
significant changes in migration of A10 cells exposed to the whole secretome were observed. f In order to study the effects of the total
secretome and ADSC-derived EVs on cellular senescence, IMR-90 cells were co-exposed to H2O2 and vehicle (PBS), whole secretome, and the EV-
fraction followed by staining for β-Galactosidase activity. Analysis of the number of senescent cells revealed that both total ADSC secretome and
the EV fraction protect against cellular senescence. g, h Only the EV fraction (arrows) significantly reduces levels of inflammation in the U251 cell
model compared to the TNF-α exposed control cells showing high level of nuclear p65 (arrowheads). Scale bar: 20 μm. p < 0.05 (*), p < 0.01 (**) or
p < 0.001 (***). Three separate batches of ADSC secretome and isolated EV fraction were tested
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to that of the ADSC secretome and tested it under many
of the same in vitro assays as the ADSC secretome. The
fibroblast secretome contained a much lower total protein
concentration than the ADSC whole secretome (46 μg/mL
compared to 206 μg/mL) (Additional file 2: Figure S2A).
NTA of the fibroblast vesicle content identified a similarly
lower vesicle concentration (2.39 × 108 vesicles/mL),whilst having a similar size distribution (137 nm mean
size) to the ADSC EV (Additional file 2: Figure S2B-C).
Treating the C2C12 cells with the fibroblast secre-
tome for 48 h saw no significant increase in cell prolif-
eration (Additional file 2: Figure S2D), and there was
also no effect on the rate of cell fusion, a measure of
myogenic differentiation (Additional file 2: Figure S2E).
Finally, carrying out a migration assay saw a slight, but
Mitchell et al. Stem Cell Research & Therapy          (2019) 10:116 Page 9 of 19non-significant increase in gap closure (Additional file 2:
Figure S2F).
Total ADSC secretome and the isolated EV fraction
modulate different aspects of in vivo regeneration in the
CTX-induced acute muscle injury model
An acute CTX-induced muscle injury model was used to
assess the impact of a systemic administration of either
the whole ADSC secretome or the EV fraction on tissue
regeneration. The staining for acid phosphatase (a
marker for lysosomal activity) was carried out to quan-
tify the level of muscle degeneration 5 days after the
CTX injection. We found a significant decrease in the
lysosomal activity in mice that had been treated with the
whole ADSC secretome (Fig. 3a–c) indicating an in-
crease in regeneration.
In order to comparatively quantify the effects of the
total ADSC secretome and the EV fraction on muscle re-
generation, we quantified the cross-sectional area (CSA)
of newly formed muscle fibres identified by the expres-
sion of embryonic myosin heavy-chain (eMHC). We
found that mice treated with the total ADSC secretome
had significantly larger newly formed fibres compared to
PBS-treated animals (Fig. 3d–g). Notably, the EV frac-
tion displayed a much greater effect than the whole
secretome (Fig. 3g).
To further dissect the cellular mechanisms underpin-
ning the muscle regeneration, we quantified the myo-
genic cell populations in the damaged tissue. Our results
showed a significant increase in the number of quiescent
satellite cells (Pax7+/MyoD−) in the damaged tissue of
total ADSC secretome-treated mice and a slight non-
significant increase after the EV treatment (Fig. 3h, i).
Analysis of differentiated satellite cells (Pax7−/MyoD+)
revealed a significant decrease of Pax7−/MyoD+ cells in
mice treated with the EV fraction whereas no difference
was observed between total secretome-treated animals
and the controls (Fig. 3j, k). In contrast, both fractions
decreased the number of infiltrating macrophages
(Fig. 3l–o) with the EV fraction having a significantly
stronger effect. An additional analysis of angiogenesis
showed a significant increase of CD31+ cells within
damaged areas compared to the controls. Notably, the
EV fraction was identified to have no pro-angiogenic
effect (Fig. 3p–s).
Characterisation of the soluble proteins and the ADSC EV
protein cargo
LC–MS profiling with subsequent bioinformatic ana-
lysis showed a great overlap (49%) between the se-
creted proteins and the EV fractions with 384 of 781
proteins being mutually exclusive (Fig. 4a, b). Three
hundred one proteins (38.5%) were exclusively found
in EVs, and 96 (12.3%) only in the soluble fraction(Fig. 4b). This analysis also identified many
exosome-specific proteins within the EV fraction
(Additional file 3: Table S1). Analysis of clustering
protein abundances identified a distinctively different
profile between the proteins enriched in the soluble
fraction compared to the EV fraction (Fig. 4a). Within
the total ADSC secretome, several proteins involved
in RNA metabolism have been identified using GO
Enrichment Analysis (Additional file 3: Table S2). Sur-
prisingly, no cellular processes were found to be sig-
nificantly enriched within the soluble fraction, and
many processes within the EV fraction were involved
in protein complex disassembly and associated with
the membrane (Additional file 3: Table S3).ADSC-derived EVs contain miRNA targeting processes
involved in regeneration and regulation of inflammation
EVs were isolated from total secretome of three inde-
pendent ADSC culture and the miRNA content of
ADSC EV was analysed using a GeneChip® miRNA 4.0
array with the Affymetrix Expression Console™ software.
We were able to detect a wide range of miRNA previ-
ously associated with regulation of regeneration and in-
flammation including the let 7 family [51] and miR145
[52] as well miRNAs known to target angiogenesis-
related pathways (miR23a [53]).
Top 50 miRNAs were plotted in a heat map to show
the intensity variability between the samples (Fig. 5a).
Validated miRNA targets were amalgamated using
miRWalk2.0 software, and their biological processes
were categorised using GL Slim classification with Web-
Gestalt software. This analysis identified a total of
22,903 validated targets of the miRNAs, with over half
of the mRNA targets being linked to just four biological
processes: metabolic processes, biological regulation, re-
sponse to stimulus and multicellular organismal process
(Fig. 5b). Mapping of the individual validated targets to
biological processes found a large proportion (29.92%) to
be linked to signal transduction (Fig. 5c).ADSC and AFSC secretomes have a distinct molecular
profile despite similar biological activity in muscle
regeneration
Finally, we have taken a bioinformatic approach to com-
pare molecular components of the ADSC secretome
with the secretome of AFSCs that also promotes muscle
regeneration [38]. Using this approach, we found 108
mutually exclusive protein hits in the EV fractions of
both secretomes and 50 proteins present in both soluble
fractions (Fig. 6a).
Interestingly, 269 proteins were mutually expressed in
both fractions of ADSCs and AFSCs (Fig. 6a). Functional
enrichment analysis of all fractions revealed strong
Fig. 3 (See legend on next page.)
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Fig. 3 Total ADSC secretome and its EV fraction modulate different aspects of in vivo skeletal muscle regeneration. The regenerative effect of an
intravenous injection of either total ADSC secretome or its isolated EV fraction was assessed in the acute skeletal muscle degeneration model
induced by CTX injection into the right tibialis anterior muscle. a–c Staining for acid phosphatase revealed a significant decrease in the lysosomal
activity in mice that had been treated with the whole ADSC secretome. d–g Quantification of the cross-sectional area (CSA) demonstrated that
the skeletal muscle regeneration is significantly enhanced by whole secretome, with a greater effect with the EV fraction. Scale bar: 100 μm. h–k
Immunohistochemical staining and quantification of satellite cell myogenic progression showed an increase in the number of quiescent (Pax7+/
MyoD−) satellite cells following whole secretome treatment. Both the whole secretome and the EV fraction decrease the number of activated
(Pax7+/MyoD+) satellite cells, with a decrease in the number of differentiating satellite cells (Pax7−/MyoD+) only observed following treatment
with the EV fraction (red arrow: quiescent satellite cell, yellow arrow: differentiating satellite cell, white arrow: activated satellite cell. Scale bar:
20 μm. l–o Immunohistochemical stainings for CD68 revealed that both fractions of ADSC secretome decreased the number of infiltrating
macrophages. Scale bar: 50 μm. p–s Immunohistochemical analysis of CD31 within the muscle tissue showed that only the total secretome had
an angiogenic effect. Scale bar: 100 μm. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). Three separate batches of ADSC secretome and isolated EV
fraction were tested
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osis (Additional file 3: Table S4).
Principal component analysis (PCA) of all samples re-
vealed that EV fractions of both cell types mainly con-
tain proteins linked to ‘cotranslational protein targeting
to the membrane’ (Fig. 6b, Additional file 3: Table S5)
whereas proteins mutually present in the solubleA
Fig. 4 LC–MS analysis of total ADSC secretome vs. EV fraction revealed exc
the proteins enriched within either the soluble or EV fractions of the ADSC
MS analysis within the ADSC secretome. 301 were exclusively identified in
both samplesfractions were classified as ‘proteins involved in mRNA
metabolic processes’ (Fig. 6b). In contrast to the func-
tional enrichment analysis carried out for the soluble
fractions, no considerable functional enrichment was
found (Additional file 3: Table S6).
PCA of the miRNA cargo of EVs from ADMSCs and
AFSCs revealed that the miRNA profiles are distinctB
lusively and mutually present proteins in both fractions. a Heat map of
secretome. b A total number of 781 proteins were identified from LC–
the EV fraction, 96 in the soluble fraction and 384 are identified in
Fig. 5 Analysis of the miRNA profile of ADSC secretome. Top 50 miRNA species hits within the ADSC secretome as determined by miRNA array
analysis. a Heat map showing top 50 miRNA species. b–c Database mining and functional analysis mapping the biological processes of the
22,903 mRNA target hits from the miRNA array
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and only 47 miRNAs exclusively present in ADMSC
EVs (Fig. 7b) have been identified. Notably, mutually
present miRNAs included the anti-inflammatory let7
family (Fig. 7c).
Discussion
MSCs are a clinically relevant adult stem cell population
with the potential to positively modulate muscle regen-
eration in acute and chronic muscle injury [6, 7, 54].
Conditioned media from stem cells and their EVs are
typically collected from basal medium, or complete
serum-based media [8, 19, 34, 55].
The utilisation of PBS as the carrier for EVs and sol-
uble components of the secretome reduces the risk oftransmission of xenogenic substances. Thus, the secreted
products would have the potential to be clinically com-
pliant (saline solution). The hypoxic (cell pelleted) envir-
onment also induces a cellular stress that would
enhance the secretion of molecules that may aid regen-
eration [56]. Moreover, in a model of muscle degener-
ation, EVs isolated from MSCs cultivated under hypoxic
conditions have shown to be more efficient in promoting
regeneration than EV from normoxic MSCs [19].
Our characterisation of the total ADSC secretome, the
isolated EV fraction and the EV-depleted (soluble) frac-
tion showed that each contained a distinct spectrum of
proteins (Fig. 1a, b). Although the presence of mRNA
molecules has been reported in secretomes of MSCs in
other groups [3], we did not detect RNA molecules
Fig. 6 (See legend on next page.)
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Fig. 6 Comparative analysis of the proteins in soluble and EV fractions within the secretome of ADSCs and AFSCs revealed distinct profiles. a
Numerical Venn diagram of identified hits. b PCA analysis using the entire dataset and c 269 proteins identified in all samples, highlighted in
both b and c the most represented GO terms categories based on Benjamini-Hochberg FDR values. d Heat map reporting all identified hits and
considering log2-transformed iBAQ quantification values
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of mRNA molecules in the ADSC secretome is consist-
ent with our results obtained with AFSC secretome and
might be a consequence of the collection protocol [38].
Using TEM and NTA, we show that the EVs had an
average size of 57 nm, fitting well with the reported
characteristics for exosomes (30–100 nm) [57]. Our mass
spectrometry profile allowed us to identify many
exosome-specific proteins within our EV fraction, such as
CD63, HSPs and LAMP2 (Additional file 3: Table S1) but,
however, failed to record evidence of other commonly
used exosome markers CD9 and CD81 [33, 58, 59].
Further validation of these missing proteins via western
blot also provided a negative result (data not shown).
Their absence in our EV fraction could possibly be ex-
plained by a low concentration of the proteins or via an
interference of the EV structure and composition follow-
ing the denaturation steps we carried out for both western
blot and LC–MS [60].
Using PHK67-labelled ADSC EVs and IMR-90 cells
visualised with phalloidin, we showed an intracellular
co-localisation of PKH67 and phalloidin signal suggest-
ing that our ADSC EVs were able to be taken up by host
cells in vitro (Fig. 1h, white arrow). MSC EVs are
thought to utilise the same mechanism as their parent
cell for ‘homing’ to a site of injury by using surface re-
ceptors and adhesion molecules preserved from the
MSC cytomembrane during EV formation [61].
We show that the total ADSC secretome positively af-
fects proliferation of muscle cells and provides protec-
tion against stress-induced cellular senescence. However,
in the present study, no significant effects on migration
speed have been observed (Fig. 2a, d, f ).
In the present study, we assessed the influence of
ADSC-secretome and ADSC-derived EVs on H2O2-in-
duced senescence of IMR-90 cells, a widely used model
in cell ageing research [62–64]. Notably, only the total
secretomes but not the EV fractions were able to reduce
the number of senescent cells (Fig. 2f ) suggesting that
soluble factors rather than EV cargo is responsible for
this effect.
In contrast, total ADSC failed to impact nuclear trans-
location of the NF-κB assay whereas the EV fraction did
(Fig. 2g, h), implying that the anti-inflammatory effects
of the ADSC secretome are mainly mediated by the EV
fraction. This is in line with recent reports showing
strong anti-inflammatory properties of MSC-derived EVs
in different pathological scenarios [19, 65, 66]. Carryingout similar experiments with a control fibroblast secre-
tome saw no effect on the same in vitro assays, suggest-
ing that the effects we observed are due to the
regenerative nature of the ADSC source, rather than a
concentration of secreted products.
The study of Lo Sicco et al. [19] is of particular sig-
nificance to this work, since they found that hypoxic
conditions supported the development of a potent re-
generative EV fraction. However, it seems that MSCs
are extremely labile in terms of the secretome reper-
toire. Indeed, although a number of groups have shown
that the EV fraction of MSC secretomes support
muscle regeneration [19, 67], the identity of the puta-
tive effective agents differs greatly. For example, Naka-
mura suggested that the angiogenesis supporting
property lay with non-EV VEGF and that the EV en-
capsulated miR494 promoted myogenesis. Although we
see both properties, our EV free fraction lacked VEGF,
as well as other angiogenic proteins such as SPRED1,
VECAM1 and IGF1, and the EV fraction contained low
levels of miR494. This suggests that there are multiple
routes to promote key features of muscle regeneration
and demonstrates the potential diversity that may re-
sult from differential secretome generation protocols.
In order to identify the soluble and EV-associated pro-
tein components potentially contributing to the effect
of the ADSC secretome, we performed an LC–MS pro-
filing with subsequent bioinformatic analysis (Figs. 4
and 6). We detected many proteins in the soluble frac-
tion that have previously been described in the MSC
secretome, including Heat Shock Proteins (HSPs)
(HSP60, HSP90, HSP105). HSPs are produced by cells
in response to stressful conditions, such as heat, wound
healing or inflammation [68–70] Notably, HSPs have
also been shown to enhance regeneration in MSC ther-
apies [58, 71]. Our analysis also revealed the presence
of superoxide dismutase (SOD2) that is known to me-
diate resistance to oxidative stress [72].
Paracrine factors released by MSCs are known to posi-
tively influence the levels of angiogenesis [25, 73]. In
particular, HGF, bFGF, IGF-1, and VEGF have been iden-
tified as paracrine factors responsible for the
pro-angiogenic effects of MSCs [74]. Due to the strong
pro-angiogenic effects of the total ADSC secretome but
not the EV fraction, we expected that the soluble protein
fraction would contain all or at least some of these. To
our surprise, our LC–MS analysis revealed a lack of
these growth factors within the soluble fraction. This
A B
C
Fig. 7 (See legend on next page.)
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Fig. 7 Comparative analysis of the miRNA profiles of ADSCs versus AFSCs demonstrated a distinct profile with mutually present and exclusive
miRNAs. a 2D PCA plot shows two distinct clusters along the PC1 axis that correspond to the ADSCs (red) and AFSCs (green). b Weighted Venn
diagram. The graph consists of miRNAs expressed in ADSCs (red) and in AFSCs (green). 47 miRNAs were found to be exclusively present in the
ADSC samples whereas 207 miRNA were exclusive for AFSCs. 519 miRNA were mutually found in both cell types. c Hierarchical clustering heat
map of the top 50 regulated miRNAs in multiple comparisons. MicroRNAs are displayed in the rows and samples in the columns. The expression
levels are indicated via the colour coding. The shades of blue and red refer to the absolute expression levels; the brighter the blue, the lower the
expression level, and the brighter the red, the higher the expression level. The dendrograms are based on cosine column/row clustering
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being below the sensitivity of the analysis but still exert-
ing biological activity [75].
miRNAs transported within EVs have previously been
shown to be able to regulate gene expression in distant
tissues [76]. Moreover, it has been reported that
miRNA can be released into blood plasma via pack-
aging within EVs [34, 76, 77], bound to RNA-binding
proteins such as Argonaute (Ago) or lipoprotein
complexes including high-density lipoprotein (HDL)
[78, 79]. Notably, although our LC–MS analysis did
not detect Ago, HDL is present.
Our observation that ADSC secrete a large number of
miRNA species advocates the enormous potential of its
secretome in modifying the surrounding microenviron-
ment, with each miRNA possibly effecting hundreds of
different mRNA targets, and therefore being able to
affect numerous signalling pathways [80].
Analysis of the miRNAs within the EV fraction of
the ADSC secretome revealed a presence of many
well-characterised anti-inflammatory miRNAs, includ-
ing the miR-let7 family (let7a, b, c and e). miR-let7c
in particular has been demonstrated to be expressed
at a higher level in anti-inflammatory M2 macro-
phages [81] and to play an important role in reducing
fibrosis, a key factor in chronic inflammation [82]. In
contrast, let 7b, another let7 family member identified
in the top 50 miRNA species, targets the pro-
inflammatory signalling axis of TLR4 [83]. Notably,
let7b within MSC EVs has previously been reported
to be able to modify macrophage polarisation towards
the anti-inflammatory M2 phenotype [51]. We were
also able to detect miRNA targeting other down-
stream molecules in the Toll-like receptor signalling
pathway including miR-24 (targets: MyD88 and
NF-κB [84]), miR-125b (targets: IL-6, TNF-α [85, 86])
and miR-16 (target: IKK-α [87]).
Overall, we found that a large proportion of the vali-
dated miRNA targets play a role in the regulation of im-
mune systems processes, immunological development
and in the regulation of the innate immune response.
Moreover, two of the top 50 miRNAs within the ADSC
EVs, miR-23a and miR-23b, are known to be strongly
pro-angiogenic [53].A brief comparison of the miRNA content within
the ADSC secretome and those described in literature
[19, 38, 88] identifies that the pre-conditioning proto-
col utilised to generate a secretome may be the key
factor governing the miRNA cargo rather than the
cell type (Additional file 3: Table S7).
In order to compare the active compounds within the
ADSC secretome to another secretome recently de-
scribed to promote muscle regeneration (AFSCs [38]),
we performed an in-depth bioinformatic analysis of the
respective soluble and EV fractions (Fig. 6), identifying
numerous mutually exclusive proteins in each of the dif-
ferent fractions. A PCA and cluster analysis revealed
that secretomes of both stem cell populations have a dis-
tinct protein profile despite similar biological activity.
GO enrichment analysis of the whole dataset showed
that all clusters were mostly associated with ‘mRNA
metabolic processes’ and ‘cotranslational protein target-
ing to membrane’ whereas that the mutually exclusive
hits were mostly classified as ‘unspecified GO terms’.
PCA showed distinct clustering for both stem cell
types further unlinking the differences in the miRNA
cargo (Fig. 6b–d). Notably, several mutually exclusive
miRNAs were anti-inflammatory including let7b, miR-22
[89], miR-199a (target: NF-κB pathway) [90] and the key
switch in inflammatory response miR-21 [91]. Moreover,
we were also able to detect the pro-angiogenic miR-132
[92]. Interestingly, although present in both fractions,
members of the let7 family showed highly differential ex-
pression level. This comparative analysis of the protein
and miRNA components of both stem cell types reveals
distinct profiles despite similar biological effects in
muscle regeneration.Conclusions
Overall, our data suggest that soluble and EV-associated
factors promote muscle regeneration both in vitro and
in vivo in a highly synergistic manner. This is supported
by our findings showing that both fractions affect differ-
ent aspects of tissue regeneration after muscle injury.
Moreover, our comparative analysis of ADSC and AFSC
secretomes indicates that different molecular factors
might mediate similar beneficial biological outcomes.
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Additional file 1: Figure S1. ADSCs retain their multipotency following
secretome generation. (A–B) FACS analysis before and after generation of
the secretome revealed that there was no change in expression pattern
of ADSCs after 24 h in PBS. (C) Surviving cells readily differentiated into
Alizarin Red-positive osteogenic cells, (D) Oil Red O-positive adipocytes, and
(E) Alcian blue-positive chondrogenic cells. Scale bar: 100 μm. (JPG 339 kb)
Additional file 2: Figure S2. (A) The secretome generated from
fibroblast cells under identical conditions to ADSC contains a significantly
lower amount of total protein. (B-C) Characterising the fibroblast EVs
using NTA found a significantly lower concentration per mL, with a
similar size range to ADSC EVs (< 500 nm). (D-F) Investigating the
functional characteristics of the fibroblast secretome found no significant
increase in cellular proliferation compared to PBS control (D). There was
no change from control levels of C2C12 cell fusion with treatment with
fibroblast secretome (E). Fibroblast secretome demonstrated a slight non-
significant increase in percentage gap closure on the in vitro wound
assay (F). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). Three batches of
fibroblast secretome were generated and tested. (JPG 243 kb)
Additional file 3: Table S1. Exosome proteins enriched within the EV
fraction of the whole ADSC secretome. Table S2. Soluble and EV GO-MF
terms enrichment. Table S3 EV fraction GO-MF terms enrichment. Table S4.
Top 20 significantly enriched GO BP terms secretome-wide. Table S5. Top 20
significantly enriched GO BP terms in ADSC and AFS EV fractions. Table S6.
Top significantly enriched GO BP terms in ADSC and AFS soluble fractions.
Table S7. Comparison of miRNA cargo between different ADSC and AFS cell
types and secretome pre-conditioning methods. (DOCX 51 kb)
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